Cited 31 times in
Autologous peripheral blood stem cell transplantation in children with non-Hodgkin’s lymphoma: a report from the Korean society of pediatric hematology-oncology
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 양우익 | - |
dc.contributor.author | 유철주 | - |
dc.date.accessioned | 2015-06-10T12:31:02Z | - |
dc.date.available | 2015-06-10T12:31:02Z | - |
dc.date.issued | 2006 | - |
dc.identifier.issn | 0939-5555 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/109947 | - |
dc.description.abstract | Recent development of stratified chemotherapeutic regimens has rapidly improved the survival rate of non-Hodgkin’s lymphoma (NHL) of childhood. Despite these improvements, the outcome for children with recurrent or refractory NHL remains dismal. We explored the use of high-dose chemotherapy followed by autologous peripheral blood stem cell transplantation (HDC/PBSCT) for children with either refractory or recurrent NHL, and we evaluated various factors influencing outcome of HDC/PBSCT. Thirty-three patients underwent HDC/PBSCT in 11 institutes were enrolled. All patients had refractory or recurrent NHL. Sex, stage at diagnosis, histologic subtype (lymphoblastic, Burkitt’s, and large-cell lymphoma), LDH level at diagnosis, disease status at transplantation, and preparative regimens for HDC/PBSCT were explored. In regard to the patients, six had Burkitt’s lymphoma, 13 had lymphoblastic lymphoma, and 14 had large-cell lymphoma. The 2-year event-free survival (EFS) was 59.1±9.3%. The EFS for Burkitt’s, lymphoblastic, and large-cell lymphoma was 66.7±27.2, 50.5±14.8, and 82.1±11.7%, respectively. In comparison with lymphoblastic and non-lymphoblastic lymphoma, the relative risk for lymphoblastic lymphoma was higher than the others (P=0.037). EFS between anaplastic large-cell and diffuse large-cell lymphoma was 100 and 55.6±24.9%, respectively (P=0.106). Status at transplantation was the most predictive factor for the survival after HDC/PBSCT (EFS for CR 70.8±9.5% vs non-CR 20.0±17.9%, P=0.008). Transplantation-related complications were minimal, and infection was the most prevalent complication. HDC/PBSCT is considered applicable to recurrent or refractory pediatric NHL patients safely and it could replace conventional chemotherapy. In this study, children with CR status at the time of HDC/PBSCT showed higher survival rate. However, refractory or recurrent lymphoblastic lymphoma patients showed dismal results. Therefore, new therapeutic modalities may be needed for this group of NHL patients. | - |
dc.description.statementOfResponsibility | open | - |
dc.format.extent | 787~794 | - |
dc.relation.isPartOf | ANNALS OF HEMATOLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Adolescent | - |
dc.subject.MESH | Child | - |
dc.subject.MESH | Child, Preschool | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Infant | - |
dc.subject.MESH | Korea | - |
dc.subject.MESH | Lymphoma, Non-Hodgkin/mortality | - |
dc.subject.MESH | Lymphoma, Non-Hodgkin/therapy* | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Peripheral Blood Stem Cell Transplantation* | - |
dc.subject.MESH | Retrospective Studies | - |
dc.subject.MESH | Salvage Therapy | - |
dc.subject.MESH | Survival | - |
dc.subject.MESH | Survival Analysis | - |
dc.subject.MESH | Transplantation, Autologous | - |
dc.subject.MESH | Treatment Outcome | - |
dc.title | Autologous peripheral blood stem cell transplantation in children with non-Hodgkin’s lymphoma: a report from the Korean society of pediatric hematology-oncology | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Pathology (병리학) | - |
dc.contributor.googleauthor | Sung Chul Won | - |
dc.contributor.googleauthor | Jung Woo Han | - |
dc.contributor.googleauthor | Seung Yeon Kwon | - |
dc.contributor.googleauthor | Hee-Young Shin | - |
dc.contributor.googleauthor | Hyo-Seop Ahn | - |
dc.contributor.googleauthor | Tae Ju Hwang | - |
dc.contributor.googleauthor | Woo Ick Yang | - |
dc.contributor.googleauthor | Chuhl Joo Lyu | - |
dc.identifier.doi | 10.1007/s00277-006-0169-2 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A02300 | - |
dc.contributor.localId | A02524 | - |
dc.relation.journalcode | J00161 | - |
dc.identifier.eissn | 1432-0584 | - |
dc.identifier.pmid | 16932891 | - |
dc.identifier.url | http://link.springer.com/article/10.1007%2Fs00277-006-0169-2 | - |
dc.subject.keyword | Children | - |
dc.subject.keyword | Non-Hodgkin’s lymphoma | - |
dc.subject.keyword | Stem cell transplantation | - |
dc.contributor.alternativeName | Yang, Woo Ick | - |
dc.contributor.alternativeName | Lyu, Chuhl Joo | - |
dc.contributor.affiliatedAuthor | Yang, Woo Ick | - |
dc.contributor.affiliatedAuthor | Lyu, Chuhl Joo | - |
dc.rights.accessRights | not free | - |
dc.citation.volume | 85 | - |
dc.citation.number | 11 | - |
dc.citation.startPage | 787 | - |
dc.citation.endPage | 794 | - |
dc.identifier.bibliographicCitation | ANNALS OF HEMATOLOGY, Vol.85(11) : 787-794, 2006 | - |
dc.identifier.rimsid | 55038 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.